elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q37375947-32453F93-C897-4BED-A33D-2089B8EBC069
Q37375947-32453F93-C897-4BED-A33D-2089B8EBC069
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37375947-32453F93-C897-4BED-A33D-2089B8EBC069
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
P2860
Q37375947-32453F93-C897-4BED-A33D-2089B8EBC069
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37375947-32453F93-C897-4BED-A33D-2089B8EBC069
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9ba33e0544b2ce2571b866c3ccf59932ee8be785
P2860
Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.